The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products
Open accessAbstract
Polyethylene glycol (PEG) is a versatile polymer that is widely used as an additive in foods and cosmetics, and as a carrier in PEGylated therapeutics. Even though PEG is thought to be less immunogenic, or perhaps even non-immunogenic, with a variety of physicochemical properties, there is mounting evidence that PEG causes immunogenic responses when conjugated with other materials such as proteins and nanocarriers. Under these conditions, PEG with other materials can result in the production of anti-PEG antibodies after administration. The antibodies that are induced seem to have a deleterious impact on the therapeutic efficacy of subsequently administered PEGylated formulations. In addition, hypersensitivity to PEGylated formulations could be a significant barrier to the utility of PEGylated products. Several reports have linked the presence of anti-PEG antibodies to incidences of complement activation-related pseudoallergy (CARPA) following the administration of PEGylated formulations. The use of COVID-19 mRNA vaccines, which are composed mainly of PEGylated lipid nanoparticles (LNPs), has recently gained wide acceptance, although many cases of post-vaccination hypersensitivity have been documented. Therefore, our review focuses not only on the importance of PEGs and its great role in improving the therapeutic efficacy of various medications, but also on the hypersensitivity reactions attributed to the use of PEGylated products that include PEG-based mRNA COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Solubilizing Excipients in Oral and Injectable Formulations
Strickley, R. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016235.32639.23 · Cited by 1,415
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
Caliceti, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00108-x · Cited by 947
Overview of complement activation and regulation
Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Self-citationArmstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Self-citationHoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
PEG — A versatile conjugating ligand for drugs and drug delivery systems
Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.046 · Cited by 648
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A. (2000) · Annals of Oncology · doi:10.1023/a:1008365716693 · Cited by 618
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G., & Richette, P. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.720969 · Cited by 587
Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021) · PubMed · doi:10.26355/eurrev_202102_24877 · Cited by 564
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
PEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523
Self-citationThe role of complement in inflammation and phagocytosis
Frank, M. M., & Fries, L. F. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90009-i · Cited by 503
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes
Ishida, T., & Kiwada, H. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.005 · Cited by 490
Self-citationManagement and Preparedness for Infusion and Hypersensitivity Reactions
Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479
Shimabukuro, T. T., Cole, M., & Su, J. R. (2021) · JAMA · doi:10.1001/jama.2021.1967 · Cited by 475
Anaphylaxis—a practice parameter update 2015
Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., et al. (2015) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2015.07.019 · Cited by 474
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Stylianopoulos, T., Poh, M.-Z., Insin, N., Bawendi, M. G., Fukumura, D., Munn, L. L., & Jain, R. K. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.06.016 · Cited by 443
BNT162b2 mRNA COVID-19 Vaccine: First Approval
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01480-7 · Cited by 424
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Wang, X., Ishida, T., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.010 · Cited by 421
Self-citationPEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Milla, P., Dosio, F., & Cattel, L. (2012) · Current Drug Metabolism · doi:10.2174/138920012798356934 · Cited by 419
Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products
Fruijtier-Pölloth, C. (2005) · Toxicology · doi:10.1016/j.tox.2005.06.001 · Cited by 407
Semple, S. C., Chonn, A., & Cullis, P. R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00128-2 · Cited by 402
Oxidation of polyethylene glycols by alcohol dehydrogenase
Herold, D. A., Keil, K., & Bruns, D. E. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90151-2 · Cited by 400
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner
Ishida, T., Wang, X., Shimizu, T., Nawata, K., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.015 · Cited by 382
Self-citationYang, Q., Jacobs, T. M., McCallen, J. D., Moore, D. T., Huckaby, J. T., Edelstein, J. N., & Lai, S. K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03437 · Cited by 370
Immediate‐type hypersensitivity to polyethylene glycols: a review
Wenande, E., & Garvey, L. H. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12760 · Cited by 354
Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
The Immunogenicity of Polyethylene Glycol: Facts and Fiction
Schellekens, H., Hennink, W. E., & Brinks, V. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1067-7 · Cited by 340
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
Park, J., Fong, P. M., Lu, J., Russell, K. S., Booth, C. J., Saltzman, W. M., & Fahmy, T. M. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.02.002 · Cited by 339
Accelerated clearance of PEGylated liposomes in rats after repeated injections
Ishida, T., Maeda, R., Ichihara, M., Irimura, K., & Kiwada, H. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00462-5 · Cited by 327
Self-citationThe enhanced permeability retention effect: a new paradigm for drug targeting in infection
Azzopardi, E. A., Ferguson, E. L., & Thomas, D. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks379 · Cited by 312
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizón, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., & Zalipsky, S. (2003) · PubMed · Cited by 295
Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., Katsaros, D., Priolo, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6606 · Cited by 289
Ishida, T., Atobe, K., Wang, X., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.017 · Cited by 287
Self-citationThe enzyme as drug: application of enzymes as pharmaceuticals
Vellard, M. (2003) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(03)00092-2 · Cited by 283
Richter, A. W., & Åkerblom, E. (1983) · International Archives of Allergy and Immunology · doi:10.1159/000233309 · Cited by 282
Judge, A., McClintock, K., Phelps, J. R., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280
Ganson, N. J., Povsic, T. J., Sullenger, B. A., Alexander, J. H., Zelenkofske, S. L., Sailstad, J. M., Rusconi, C. P., & Hershfield, M. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.034 · Cited by 273
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7004e1 · Cited by 269
LABORATORY SYNTHESIS OF POLYETHYLENE GLYCOL DERIVATIVES
Harris, J. M. (1985) · Journal of Macromolecular Science, Part C · doi:10.1080/07366578508081960 · Cited by 267
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J., & Schellekens, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.015 · Cited by 267
Hershfield, M. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Jaggers, D. A., & Sundy, J. S. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4500 · Cited by 266
Lipsky, P. E., Calabrese, L. H., Kavanaugh, A., Sundy, J. S., Wright, D., Wolfson, M., & Becker, M. A. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4497 · Cited by 266
Thomas, A., Müller, S. S., & Frey, H. (2014) · Biomacromolecules · doi:10.1021/bm5002608 · Cited by 264
Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260
Structure and function of the anaphylatoxins
Hugh, T. E. (1984) · Springer Seminars in Immunopathology · doi:10.1007/bf01893020 · Cited by 259
Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine
Sellaturay, P., Nasser, S., Islam, S., Gurugama, P., & Ewan, P. W. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13874 · Cited by 259
Hamad, I., Hunter, A. C., Szebeni, J., & Moghimi, S. M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.08.276 · Cited by 253
Measurements of Intestinal Permeability Using Low Molecular Weight Polyethylene Glycols (PEG 400)
Chadwick, V. S., Phillips, S. F., & Hofmann, A. F. (1977) · Gastroenterology · doi:10.1016/s0016-5085(19)32197-3 · Cited by 250
What is the future of PEGylated therapies?
Swierczewska, M., Lee, K. C., & Lee, S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1113254 · Cited by 249
Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C
Rajender Reddy, K., Modi, M. W., & Pedder, S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00028-5 · Cited by 241
Pegylation: engineering improved pharmaceuticals for enhanced therapy
Molineux, G. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)80004-4 · Cited by 225
Suzuki, T., Suzuki, Y., Hihara, T., Kubara, K., Kondo, K., Hyodo, K., Yamazaki, K., Ishida, T., & Ishihara, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119792 · Cited by 225
Self-citationPolyethylene Glycol–Induced Systemic Allergic Reactions (Anaphylaxis)
Sellaturay, P., Nasser, S., & Ewan, P. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.029 · Cited by 225
Szebeni, J., Bedőcs, P., Rozsnyay, Z., Weiszhár, Z., Urbanics, R., Rosivall, L., Cohen, R., Garbuzenko, O., Báthori, G., Tóth, M., et al. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.06.003 · Cited by 219
Kozma, G. T., Mészáros, T., Vashegyi, I., Fülöp, T., Örfi, E., Dézsi, L., Rosivall, L., Bavli, Y., Urbanics, R., Mollnes, T. E., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b03942 · Cited by 214
Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., & Hope, M. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078113 · Cited by 211
Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review
Shiraishi, K., & Yokoyama, M. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1590126 · Cited by 208
Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS
James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., & Stewart, J. S. W. (1994) · Clinical Oncology · doi:10.1016/s0936-6555(05)80269-9 · Cited by 205
Safety Evaluation of Polyethylene Glycol (PEG) Compounds for Cosmetic Use
Jang, H.-J., Shin, C. Y., & Kim, K.-B. (2015) · Toxicological Research · doi:10.5487/tr.2015.31.2.105 · Cited by 204
Schreiber, I., Buchfelder, M., Droste, M., Forssmann, K., Mann, K., Saller, B., & Strasburger, C. J. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02312 · Cited by 202
Szebeni, J., Alving, C. R., Rosivall, L., Bünger, R., Baranyi, L., Bedöcs, P., Tóth, M., & Barenholz, Y. (2007) · Journal of Liposome Research · doi:10.1080/08982100701375118 · Cited by 199
Povsic, T. J., Lawrence, M. G., Lincoff, A. M., Mehran, R., Rusconi, C. P., Zelenkofske, S. L., Huang, Z., Sailstad, J., Armstrong, P. W., Steg, P. G., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.058 · Cited by 197
Hu, Y., Daoud, W., Cheuk, K., & Lin, C. (2016) · Materials · doi:10.3390/ma9030133 · Cited by 194
Cytotoxicity study of polyethylene glycol derivatives
Liu, G., Li, Y., Yang, L., Wei, Y., Wang, X., Wang, Z., & Tao, L. (2017) · RSC Advances · doi:10.1039/c7ra00861a · Cited by 194
Accelerated clearance of a second injection of PEGylated liposomes in mice
Ishida, T., Masuda, K., Ichikawa, T., Ichihara, M., Irimura, K., & Kiwada, H. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00085-1 · Cited by 183
Self-citationSzebeni, J., Baranyi, L., Savay, S., Bodo, M., Morse, D. S., Basta, M., Stahl, G. L., Bünger, R., & Alving, C. R. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h1319 · Cited by 171
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats
Ichihara, M., Shimizu, T., Imoto, A., Hashiguchi, Y., Uehara, Y., Ishida, T., & Kiwada, H. (2010) · Pharmaceutics · doi:10.3390/pharmaceutics3010001 · Cited by 168
Self-citationLongo, N., Harding, C. O., Burton, B. K., Grange, D. K., Vockley, J., Wasserstein, M., Rice, G. M., Dorenbaum, A., Neuenburg, J. K., Musson, D. G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61841-3 · Cited by 167
Bukowski, R. M., Tendler, C., Cutler, D., Rose, E., Laughlin, M. M., & Statkevich, P. (2002) · Cancer · doi:10.1002/cncr.10663 · Cited by 166
Foser, S., Schacher, A., Weyer, K. A., Brugger, D., Dietel, E., Marti, S., & Schreitmüller, T. (2003) · Protein Expression and Purification · doi:10.1016/s1046-5928(03)00055-x · Cited by 165
Gao, H., & He, Q. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.877442 · Cited by 164
Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdiş, C. A., & Novak, N. (2020) · Allergy · doi:10.1111/all.14711 · Cited by 157
Classification of hypersensitivity reactions
Dispenza, M. C. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4274 · Cited by 156
Development of aptamer therapeutics
Bunka, D. H. J., Platonova, O., & Stockley, P. G. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.009 · Cited by 153
Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
Garvey, L. H., & Nasser, S. M. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.12.020 · Cited by 151
Szebeni, J. (2001) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v18.i6.50 · Cited by 147
Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility
Müller, C. E. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900114 · Cited by 146
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing
Wolfson, A. R., Robinson, L. B., Li, L., McMahon, A. E., Cogan, A. S., Fu, X., Wickner, P. G., Samarakoon, U., Saff, R. R., Blumenthal, K. G., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.010 · Cited by 140
Fate of Water‐Soluble Polymers Administered via Different Routes
Yamaoka, T., Tabata, Y., & Ikada, Y. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840316 · Cited by 130
Role of complement activation in atherosclerosis
Oksjoki, R., Kovanen, P. T., & Pentikäinen, M. O. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00008 · Cited by 130
Lipid Nanoparticle-Mediated Delivery of mRNA Therapeutics and Vaccines
Swingle, K. L., Hamilton, A. G., & Mitchell, M. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.003 · Cited by 129
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients
Jakasa, I., Verberk, M. M., Esposito, M., Bos, J. D., & Kezic, S. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700582 · Cited by 124
A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
Hu, X. S., Miller, L., Richman, S., Hitchman, S., Glick, G., Liu, S., Zhu, Y., Crossman, M., Nestorov, I. A., Gronke, R. S., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011407068 · Cited by 119
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose
Chagla, Z. (2021) · Annals of Internal Medicine · doi:10.7326/acpj202102160-015 · Cited by 119
Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
O’Shaughnessy, J. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.037 · Cited by 117
Hsieh, Y.-C., Wang, H.-E., Lin, W.-W., Roffler, S. R., Cheng, T.-C., Su, Y.-C., Li, J.-J., Chen, C., Huang, C.-H., Chen, B., et al. (2018) · Theranostics · doi:10.7150/thno.22164 · Cited by 116
Antibodies against polyethylene glycol in human blood: A literature review
Lu, H., Wang, Z., Wei, X., Shi, J., & Li, C. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106678 · Cited by 113
Szebeni, J., & Storm, G. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.177 · Cited by 111
Firdessa, R., Oelschlaeger, T. A., & Moll, H. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2014.08.001 · Cited by 107
Pedersen, M. B., Zhou, X., Larsen, E., Sørensen, U. B. S., Kjems, J., Nygaard, J. V., Nyengaard, J. R., Meyer, R. L., Boesen, T. P., & Vorup‐Jensen, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902214 · Cited by 106
Shimizu, T., Ichihara, M., Yoshioka, Y., Ishida, T., Nakagawa, S., & Kiwada, H. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00276 · Cited by 106
Self-citationHoy, S. M. (2021) · Drugs · doi:10.1007/s40265-021-01560-8 · Cited by 106
Dézsi, L., Fülöp, T., Mészáros, T., Szénási, G., Urbanics, R., Vázsonyi, C., Őrfi, E., Rosivall, L., Nemes, R., Kok, R. J., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.009 · Cited by 100
Immediate and delayed allergic contact reactions to polyethylene glycol
Fisher, A. A. (1978) · Contact Dermatitis · doi:10.1111/j.1600-0536.1978.tb03759.x · Cited by 97
Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes
Chauhan, S. C., Yallapu, M. M., Ebeling, Chauhan, & Jaggi (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s25534 · Cited by 96
Activation of Serum Complement by Contrast Media
Lang, J. H., Lasser, E. C., & Kolb, W. P. (1976) · Investigative Radiology · doi:10.1097/00004424-197607000-00007 · Cited by 94
The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®)
Szebeni, J., Baranyi, L., Sávay, S., Lutz, H. U., Jelezarova, E., Bünger, R., & Alving, C. R. (2000) · Journal of Liposome Research · doi:10.3109/08982100009031112 · Cited by 93
Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m4826 · Cited by 93
The Chronic Oral Toxicology of thePolyethylene Glycols*
SMYTH, H. F., Carpenter, C. P., & Weil, C. S. (1955) · Journal of the American Pharmaceutical Association (Scientific ed ) · doi:10.1002/jps.3030440111 · Cited by 92
Emam, S. E., Elsadek, N. E., Lila, A. S. A., Takata, H., Kawaguchi, Y., Shimizu, T., Ando, H., Ishima, Y., & Ishida, T. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.001 · Cited by 92
Self-citationd’Avanzo, N., Celia, C., Barone, A., Carafa, M., Marzio, L. D., Santos, H. A., & Fresta, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900170 · Cited by 88
Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis
Ling, Y., Zhong, J., & Luo, J. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27203 · Cited by 85
PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol
Cox, F., Khalib, K., & Conlon, N. P. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1824 · Cited by 84
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary
Markman, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.11.1469 · Cited by 82
Methoxy Polyethylene Glycol-Epoetin Beta
Curran, M. P., & McCormack, P. L. (2008) · Drugs · doi:10.2165/00003495-200868080-00009 · Cited by 81
Fukuda, A., Tahara, K., Hane, Y., Matsui, T., Sasaoka, S., Hatahira, H., Motooka, Y., Hasegawa, S., Naganuma, M., Abe, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185654 · Cited by 81
Choi, J. S., & Jo, B.-W. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.05.014 · Cited by 77
Binding of plasma proteins to titanium dioxide nanotubes with different diameters
Iglič, A., Kulkarni, M., Flašker, A., Lokar, M., Mrak‐Poljšak, K., Mazare, A., Artenjak, A., Čučnik, S., Kralj, S., Velikonja, A., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s77492 · Cited by 77
Gupta, S., Lau, K., Harding, C. O., Shepherd, G. M., Boyer, R., Atkinson, J. P., Knight, V., Olbertz, J., Larimore, K., Gu, Z., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.038 · Cited by 77
Improving the Treatment of Acute Lymphoblastic Leukemia
Radadiya, A., Zhu, W., Coricello, A., Alcaro, S., & Richards, N. G. J. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00354 · Cited by 75
Rau, R. E., Dreyer, Z. E., Choi, M. R., Wei, L., Skowroński, R., Allamneni, K. P., Devidas, M., Raetz, E. A., Adamson, P. C., Blaney, S. M., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26873 · Cited by 70
Hypersensitivity to Polyethylene Glycols
Shah, S., Prematta, T., Adkinson, N. F., & Ishmael, F. T. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012447122 · Cited by 65
Toxicity of topical polyethylene glycol
Herold, D. A., Rodeheaver, G. T., Bellamy, W. T., Fitton, L. A., Bruns, D. E., & Edlich, R. F. (1982) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(82)90016-3 · Cited by 63
Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m4709 · Cited by 63
Immunogenicity of Polyethylene Glycol (PEG)
Garay, R. P. (2011) · The Open Conference Proceedings Journal · doi:10.2174/2210289201102010104 · Cited by 60
Bai, M., & Liu, S.-Z. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.02.051 · Cited by 56
A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid
Borderé, A., Stockman, A., Boone, B., Franki, A., Coppens, M. J., Lapeere, H., & Lambert, J. (2012) · Contact Dermatitis · doi:10.1111/j.1600-0536.2012.02104.x · Cited by 54
Hasan, H., Shaikh, O. M., Rassekh, S. R., Howard, A. F., & Goddard, K. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26200 · Cited by 52
Effect of DOPE and cholesterol on the protein adsorption onto lipid nanoparticles
Caracciolo, G., Pozzi, D., Capriotti, A. L., Cavaliere, C., & Laganà, A. (2013) · Journal of Nanoparticle Research · doi:10.1007/s11051-013-1498-4 · Cited by 51
Wenande, E. C., Skov, P. S., Mosbech, H., Poulsen, L. K., & Garvey, L. H. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.09.037 · Cited by 51
Harashima, H., HUONG, T. M., Ishida, T., Manabe, Y., Matsuo, H., & Kiwada, H. (1996) · Pharmaceutical Research · doi:10.1023/a:1016401025747 · Cited by 50
Self-citationAlinaghi, A., Rouini, M. R., Daha, F. J., & Moghimi, H. R. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.11.011 · Cited by 50
Tsai, J., Shen, L.-C., Sheu, H. M., & Lu, C.-C. (2003) · Archives of Dermatological Research · doi:10.1007/s00403-003-0414-7 · Cited by 49
Hypersensitivity reactions to radiocontrast media: The role of complement activation
Szebeni, J. (2004) · Current Allergy and Asthma Reports · doi:10.1007/s11882-004-0038-9 · Cited by 45
Elsadek, N. E., Lila, A. S. A., Emam, S. E., Shimizu, T., Takata, H., Ando, H., Ishima, Y., & Ishida, T. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.04.026 · Cited by 44
Self-citationSurface Modification of Poly Ethylene Glycol to Resist Nonspecific Adsorption of Proteins
Xi-Feng, X. I. A. O., Jiang, X., & Zhou, L. (2013) · CHINESE JOURNAL OF ANALYTICAL CHEMISTRY (CHINESE VERSION) · doi:10.3724/sp.j.1096.2013.20582 · Cited by 41
Beranová, M., Wasserbauer, R., Vančurová, D., Štifter, M., Očenášková, J., & Mára, M. (1990) · Biomaterials · doi:10.1016/0142-9612(90)90070-7 · Cited by 39
Multimeric, Multifunctional Derivatives of Poly(ethylene glycol)
Zacchigna, M., Cateni, F., Drioli, S., & Bonora, G. M. (2011) · Polymers · doi:10.3390/polym3031076 · Cited by 38
Szebeni, J. (2005) · Current Drug Delivery · doi:10.2174/156720105774370212 · Cited by 38
Oral toxicity of polyethylene glycol (PEG 200) in monkeys and rats
Prentice, D. E., & Majeed, S. K. (1978) · Toxicology Letters · doi:10.1016/0378-4274(78)90084-x · Cited by 38
Grigoletto, A., Mero, A., Zanusso, I., Schiavon, O., & Pasut, G. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500282 · Cited by 37
Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences
Kleine‐Tebbe, J., Klimek, L., Hamelmann, E. H., et al. (2021) · Allergologie select · doi:10.5414/alx02215e · Cited by 37
Parums, D. (2021) · Medical Science Monitor · doi:10.12659/msm.934625 · Cited by 36
Zhang, C., Fan, K. C., Ma, X., & Wei, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039659 · Cited by 35
Verma, A. R., Chen, K., Bender, C., Gorney, N., Leonard, W., & Barnette, P. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1634778 · Cited by 33
Vitreous Injections of Pegaptanib Sodium Triggering Allergic Reactions
Steffensmeier, A., Azar, A., Fuller, J. J., Muller, B. A., & Russell, S. R. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.10.007 · Cited by 31
Elsadek, N. E., Hondo, E., Shimizu, T., Takata, H., Lila, A. S. A., Emam, S. E., Ando, H., Ishima, Y., & Ishida, T. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00366 · Cited by 29
Self-citationBrowne, E. K., Moore, C., Sykes, A. D., Lu, Z., Jeha, S., & Mandrell, B. N. (2017) · Journal of Pediatric Oncology Nursing · doi:10.1177/1043454217741868 · Cited by 23
Immunogenicity Risk Assessment for PEGylated Therapeutics
Mora, J. R., White, J. T., & DeWall, S. L. (2020) · The AAPS Journal · doi:10.1208/s12248-020-0420-0 · Cited by 22
Leung, H., Ballantyne, B., Hermansky, S. J., & Frantz, S. W. (2000) · International Journal of Toxicology · doi:10.1080/10915810050178752 · Cited by 19
A cautionary note: Toxicity of polyethylene glycol 200 injected intraperitoneally into mice
Thiele, W., Kyjacová, L., Köhler, A., & Sleeman, J. P. (2019) · Laboratory Animals · doi:10.1177/0023677219873684 · Cited by 18
Anaphylaxis following a transvaginal ultrasound
Jakubovic, B. D., Saperia, C., & Sussman, G. L. (2016) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-015-0106-9 · Cited by 17
Sayed, M. M. E., Shimizu, T., Lila, A. S. A., Elsadek, N. E., Emam, S. E., Alaaeldin, E., Kamal, A., Sarhan, H. A., Ando, H., Ishima, Y., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121539 · Cited by 16
Self-citationAnaphylaxis to Pegylated Liposomal Doxorubicin: A Case Report
Sharma, L. R., Subedi, A., & Shah, K. (2014) · West Indian Medical Journal · doi:10.7727/wimj.2013.270 · Cited by 15
Delayed hypersensitivity reaction related to the use of pegfilgrastim
Dadla, A., Tannenbaum, S. H., Yates, B., & Holle, L. M. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214542493 · Cited by 13
Cited by
Lee, Y., Jeong, M., Park, J., Jung, H., & Lee, H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01086-x · Cited by 450
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 371
Feng, C., Wang, Y., Xu, J., Zheng, Y., Zhou, W., Wang, Y., & Luo, C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121582 · Cited by 317
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Metadata
- Authors
- Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., & Ishida, T.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 351
- Pages
- 215-230
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4296904320
- Cited by
- 465
- References
- 165
- FWCI
- 19.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.